New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
08:01 EDTHALOHalozyme upgraded to Buy from Neutral at UBS
UBS transitioned coverage on Halozyme with a Buy rating from a Neutral rating. The firm upgraded shares due to valuation and is more bullish on the PEGPH20 program following the recently removed clinical hold and believes the Herceptin-SC launch is tracking well and provides near-term support and strong uptake. Price target raised to $16 from $%14.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
12:36 EDTHALOOptions with decreasing implied volatility
Subscribe for More Information
09:04 EDTHALOBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
08:32 EDTHALOHalozyme receives FDA approval for new Hylenex recombinant facilities
Subscribe for More Information
October 7, 2014
08:34 EDTHALOHalozyme issued patent for diagnosing hyaluronan-associated diseases
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use